-transparent.png){kind=logo}
The possible use of heptakis (2,6-di-O-ethyl)-beta-cyclodextrin (DE-beta-CyD) as a parenteral sustained-release carrier for buserelin acetate, a luteinizing hormone-releasing hormone superagonist, has been examined. The in-vitro release of buserelin from the oily suspension was significantly retarded by the complexation with DE-beta-CyD, mainly due to the poor water solubility of the complex. A single subcutaneous injection of the suspension containing the buserelin-DE-beta-CyD complex to rats provided an effective continuous plasma level of buserelin lasting for at least one month, indicating a potential therapeutic efficacy for the treatment of the endocrine-dependent diseases. These results suggest that DE-beta-CyD serves as an injectable sustained-release drug carrier suitable for chronic treatment with buserelin acetate.
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
February 1997,
Chemical & pharmaceutical bulletin,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
October 1997,
Pharmaceutical research,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
December 1985,
Clinical endocrinology,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
November 1995,
Journal of pharmaceutical sciences,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
December 1995,
Chemical & pharmaceutical bulletin,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
February 1988,
The Journal of pharmacology and experimental therapeutics,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
June 1986,
Nihon Naibunpi Gakkai zasshi,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
April 1989,
Human reproduction (Oxford, England),
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
February 1990,
Journal of pharmaceutical sciences,
K Uekama, and
H Arima, and
T Irie, and
K Matsubara, and
T Kuriki
October 1988,
Fertility and sterility,
